Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
HOME > ORGANIZATION
ORGANIZATION
- Japan Hospital Federation Calls for Drug Pricing Overhaul in FY2024
December 20, 2022
- Japan Citizen’s Group Opposes NIP Inclusion of Silgard 9
December 19, 2022
- Ease API Regulations to US and European Levels to Stop Generic Woes: JEMA
December 15, 2022
- Lilly’s Simone Thomsen to Become PhRMA Japan Chair in January
December 7, 2022
- FPMAJ Poll Finds Worsening Supply Woes with 28% of Drugs Restricted or Suspended
December 7, 2022
- 88% of Japanese Have Confidence in Pharma Industry: JPMA
December 6, 2022
- Exclude Patented Drugs from Off-Year Price Revision: JPMA, PhRMA, EFPIA
November 24, 2022
- Citizen’s Group Renews Opposition to Emergency Approval of Shionogi COVID-19 Pill
November 22, 2022
- Increasing Number of Lawmakers Are Against Off-Year Price Revision: JPMA Director General
November 18, 2022
- JPMA Lauds Govt’s Proposed Extra Budget for Enhanced Startup Support
November 10, 2022
- As Arrival of Alzheimer’s Meds Nears, Experts Talk over Financial Impact and ROI: Lilly/PhRMA Forum
November 9, 2022
- Priority of Japan Investment Lowered at 27% of Multinational Firms: JPMA Poll
November 2, 2022
- JPMA Applauds Drug Discovery Startup Support in New Economic Package
October 31, 2022
- Japan Needs New Forum for Top-Level Dialogue Including Global CEOs: PhRMA Chair
October 28, 2022
- Over 80% of Wholesaler Reps Say Shipment Adjustments Take Up Most of Their Time: Survey
October 21, 2022
- Look at Drug Prices as Long-Term Investment, Not as Cost: EFPIA President
October 7, 2022
- EFPIA Chief Prods Japan on Mutual Trial Data Recognition, Cooperation to Boost Attractiveness to Rival US, China
October 7, 2022
- EFPIA Japan Appoints Takafumi Horii as New Vice Chair
October 6, 2022
- JMA Chuikyo Rep Urges Savings from Off-Year Drug Price Cuts to Be Allocated to Medical Fees
October 5, 2022
- Generic Use Rate at 79.8% in April-June, Flat YOY: JGA
September 29, 2022
ページ
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…